Sensorion S.A. (ALSEN.PA)
Sensorion S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Montpellier, OC, FR. The stock last traded at $0.28, down 2.24% on the session, giving a market capitalisation of $86.8M. Its beta of 0.42 implies it has historically moved less than the broad market.
Sensorion SA is a clinical-stage biopharmaceutical firm based in Montpellier, France, specializing in the development of therapies for inner ear disorders. Their key initiatives include gene therapy programs: OTOF-GT, designed to restore hearing for individuals with Otoferlin deficiency, and USHER-T1-GT, targeting Usher syndrome Type 1. The company also advances SENS-401, a drug candidate for treating sudden sensorineural hearing loss. Sensorion's broader pipeline encompasses numerous experimental treatments aimed at restoring, treating, and preventing various conditions affecting the inner ear. They hold a collaboration agreement with Institut Pasteur concerning gene therapy for both pediatric and adult deafness. Additionally, Sensorion partners with Sonova Holding AG to integrate genetic analysis into the routine diagnosis of progressive adult hearing loss, combining advanced therapeutic approaches with traditional hearing aids. Founded in 2009, Sensorion SA operates primarily in France.
Sensorion S.A. is most often compared with the following Healthcare names: